Mechanism of Rosiglitazone Suppressing the Activation of Hepatic Stellate Cells

郭晏同,赵景明,王欣,周迈,焦岗军,钟朝辉,李涛,冷希圣
DOI: https://doi.org/10.3969/j.issn.1002-266x.2008.19.003
2008-01-01
Abstract:Objective To identify whether the effect of rosiglitazone on the biological characters of hepatic stellate cells(HSCs) being carried out through peroxisome proliferator-activated receptor gamma(PPARγ).Methods The activated HSCs were divided into four groups: 10 μmol/L rosiglitazone group,GW9662 with 10 μmol/L rosiglitazone group,the control group and GW9662 group.The expression of PPARγ and type Ⅰ pro-collagen at mRNA level was detected by reverse transcription polymerase chain reaction(RT-PCR).The expressions of PPARγ and type Ⅰ collagen were measured by western blot.Protein binding activity of PPARγ was evaluated by electrophoretic mobility shift assay(EMSA).The variation of expression of α-SMA was measured by immunocytochemistry.Results Compared with other groups,the expression of PPARγ of mRNA and protein level in 10 μmol/L rosiglitazone group was significantly increased(P0.01),while the expression of type Ⅰpro-collagen of mRNA and protein level was significantly reduced(P0.01).Protein binding activity of PPARγ was strongest in 10 μmol/L rosiglitazone group.The expression of α-SMA in 10 μmol/L rosiglitazone group was significantly lower than those in other groups.Conclusion The effect of rosiglitazone on hepatic stellate cells of rats may be carried out through PPARγ.
What problem does this paper attempt to address?